Broad-Based Incyte/Merus Collaboration Includes Up To 11 Bispecific Antibody Programs

The US biotech is paying $200m up front in cash and equity investment for the ability to use Merus’ bispecific technology platform in up to 11 programs, which could move beyond cancer and include novel targets and biology. Potential earn-outs under the deal could reach nearly $3bn.